Metropolitan Life Insurance CO Clovis Oncology, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

40 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$1.43 - $3.14 $24,257 - $53,263	-16,963 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$2.7 - $4.76 $45,800 - $80,743	16,963 New	16,963 $45,000
Q4 2021 Mar 30, 2023	BUY	$2.7 - $4.76 $6,169 - $10,876	2,285 Added 15.57%	16,963 $45,000
Q4 2021 Feb 15, 2022	BUY	$2.7 - $4.76 $6,169 - $10,876	2,285 Added 15.57%	16,963 $46,000
Q3 2021 Jun 21, 2023	BUY	$4.06 - $5.8 $59,592 - $85,132	14,678 New	14,678 $65,000
Q3 2021 Mar 30, 2023	SELL	$4.06 - $5.8 $45,110 - $64,443	-11,111 Reduced 43.08%	14,678 $65,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $45,110 - $64,443	-11,111 Reduced 43.08%	14,678 $65,000
Q2 2021 Jun 21, 2023	BUY	$5.02 - $7.05 $129,460 - $181,812	25,789 New	25,789 $149,000
Q2 2021 Mar 30, 2023	BUY	$5.02 - $7.05 $10,757 - $15,108	2,143 Added 9.06%	25,789 $149,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $129,340 - $181,643	25,765 Added 107354.17%	25,789 $150,000
Q1 2021 Jun 26, 2023	BUY	$4.81 - $10.34 $113,737 - $244,499	23,646 New	23,646 $166 Million
Q1 2021 Mar 30, 2023	SELL	$4.81 - $10.34 $11,789 - $25,343	-2,451 Reduced 9.39%	23,646 $165,000
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $125,411 - $269,594	-26,073 Reduced 99.91%	24 $166,000
Q4 2020 Jun 22, 2023	BUY	$4.13 - $6.41 $107,780 - $167,281	26,097 New	26,097 $125,000
Q4 2020 Mar 30, 2023	BUY	$4.13 - $6.41 $2,552 - $3,961	618 Added 2.43%	26,097 $125,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $2,552 - $3,961	618 Added 2.43%	26,097 $125,000
Q3 2020 Jun 26, 2023	BUY	$4.82 - $7.72 $122,808 - $196,697	25,479 New	25,479 $148,000
Q3 2020 Mar 30, 2023	BUY	$4.82 - $7.72 $9,721 - $15,571	2,017 Added 8.6%	25,479 $148,000
Q3 2020 Nov 13, 2020	BUY	$4.82 - $7.72 $9,721 - $15,571	2,017 Added 8.6%	25,479 $149,000
Q2 2020 Jun 26, 2023	BUY	$5.69 - $9.69 $133,498 - $227,346	23,462 New	23,462 $158,000
Q2 2020 Mar 30, 2023	BUY	$5.69 - $9.69 $45,019 - $76,667	7,912 Added 50.88%	23,462 $158,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $45,019 - $76,667	7,912 Added 50.88%	23,462 $158,000
Q1 2020 Jul 12, 2023	BUY	$3.77 - $11.0 $58,623 - $171,050	15,550 New	15,550 $98,000
Q4 2019 Jul 12, 2023	BUY	$3.0 - $16.43 $46,650 - $255,486	15,550 New	15,550 $162,000
Q4 2019 Mar 30, 2023	BUY	$3.0 - $16.43 $111 - $607	37 Added 0.24%	15,550 $162,000
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $111 - $607	37 Added 0.24%	15,550 $162,000
Q3 2019 Jul 12, 2023	BUY	$3.93 - $15.35 $60,966 - $238,124	15,513 New	15,513 $60,000
Q2 2019 Jul 12, 2023	BUY	$12.81 - $25.67 $198,721 - $398,218	15,513 New	15,513 $230,000
Q1 2019 Jul 13, 2023	BUY	$17.66 - $30.28 $273,959 - $469,733	15,513 New	15,513 $385,000
Q1 2019 Mar 30, 2023	BUY	$17.66 - $30.28 $273,959 - $469,733	15,513 New	15,513 $385,000
Q1 2019 May 16, 2019	BUY	$17.66 - $30.28 $10,560 - $18,107	598 Added 4.01%	15,513 $385,000
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $10,560 - $18,107	-598 Reduced 3.85%	14,915 $573,000
Q4 2018 Jul 13, 2023	BUY	$11.63 - $32.67 $180,416 - $506,809	15,513 New	15,513 $278,000
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $140,909 - $395,829	12,116 Added 356.67%	15,513 $279,000
Q3 2018 Jul 13, 2023	BUY	$29.37 - $49.48 $455,616 - $767,583	15,513 New	15,513 $456 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $355,846 - $599,499	-12,116 Reduced 78.1%	3,397 $100,000
Q2 2018 Aug 15, 2018	BUY	$42.06 - $62.4 $49,378 - $73,257	1,174 Added 8.19%	15,513 $0
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $10,074 - $13,611	201 Added 1.42%	14,339 $0
Q4 2017 Feb 15, 2018	SELL	$57.69 - $84.58 $874,349 - $1.28 Million	-15,156 Reduced 51.74%	14,138 $961,000
Q2 2017 Aug 14, 2017	BUY	N/A	29,294	29,294 $2.74 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account